PREDAIR FORTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PREDAIR FORTE (PREDAIR FORTE).
Prednisolone is a glucocorticoid that binds to the glucocorticoid receptor, altering gene expression to produce anti-inflammatory and immunosuppressive effects.
| Metabolism | Primarily hepatic via CYP3A4, also metabolized by 11β-hydroxysteroid dehydrogenase and 20-keto reduction. |
| Excretion | Prednisolone (active metabolite of prednisone) is eliminated primarily via renal excretion of inactive metabolites (approximately 80-90%) and to a minor extent via fecal excretion (approximately 10-20%). Less than 1% of the dose is excreted unchanged in urine. |
| Half-life | The terminal elimination half-life of prednisolone is approximately 2-4 hours in adults. In children, the half-life may be shorter (1-3 hours). The half-life can be prolonged in patients with hepatic impairment or severe renal disease. This short half-life allows for alternate-day dosing to minimize hypothalamic-pituitary-adrenal (HPA) axis suppression. |
| Protein binding | Prednisolone is approximately 70-90% bound to plasma proteins, primarily to corticosteroid-binding globulin (CBG, transcortin) and albumin. Binding is concentration-dependent and saturable at high doses. |
| Volume of Distribution | The apparent volume of distribution (Vd) of prednisolone is 0.5-1.0 L/kg. This suggests distribution into total body water and some tissue binding, but limited by high protein binding. Vd may increase in hypoalbuminemia. |
| Bioavailability | Oral bioavailability of prednisolone is approximately 70-80% after a single dose, with peak plasma concentrations occurring within 1-2 hours. Food may delay absorption but does not significantly reduce total bioavailability. For prednisone (prodrug), bioavailability is similar after conversion to prednisolone. |
| Onset of Action | Oral administration: Onset of anti-inflammatory effects occurs within 2-4 hours. Peak clinical effects may be delayed for several days. Intravenous administration: Onset of action is more rapid, within minutes to hours, depending on the condition. |
| Duration of Action | The duration of anti-inflammatory and immunosuppressive effects lasts 24-36 hours after a single oral dose. Clinical effects may persist for 2-4 days after cessation of chronic therapy due to tissue binding and genomic effects. HPA axis suppression can last for weeks after discontinuation. |
| Molecular Weight | 402.48 Da |
0.5-1.5 mL (5-15 mg prednisolone equivalent) injected subconjunctivally or peribulbarly as a single dose; may repeat weekly if needed. For systemic use, 5-60 mg/day oral prednisolone equivalent, divided 1-2 times daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required for renal impairment. GFR-based modifications are not indicated as prednisolone is primarily metabolized hepatically. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25-50% due to reduced clearance. Child-Pugh C: avoid use or use with extreme caution; dose reduction of 50% or more recommended. |
| Pediatric use | Children: 0.1-2 mg/kg/day orally as prednisolone equivalent, divided 1-4 times daily, tapering to lowest effective dose. For ophthalmic use: 0.1-0.5 mL per eye as a single injection; frequency individualized. |
| Geriatric use | Use lowest effective dose with gradual taper. Monitor for osteoporosis, hyperglycemia, and cardiovascular effects. Consider osteoporosis prophylaxis (calcium, vitamin D) for long-term use. |
| 1st trimester | Avoid unless essential. Topical corticosteroids are generally preferred; systemic use is associated with increased risk of orofacial clefts (odds ratio ~3-4 with first trimester exposure). Limited data for high-potency formulations. |
| 2nd trimester | Use only if benefit outweighs risk. Chronic use may impair fetal growth; monitor for signs of adrenal suppression in newborn if used near term. |
| 3rd trimester | Use only if necessary. Prolonged use may cause fetal adrenal suppression, growth restriction, and maternal glucose intolerance. Avoid use within 2 weeks of delivery due to risk of neonatal adrenal crisis. |
Clinical note
Comprehensive clinical and safety monograph for PREDAIR FORTE (PREDAIR FORTE).
| Placental transfer | Prednisolone crosses the placenta; however, the fetal concentration is lower than maternal (fetal:maternal ratio ~0.1-0.5) due to placental 11β-hydroxysteroid dehydrogenase type 2 converting prednisolone to inactive prednisone. High doses may saturate this enzyme. |
| Breastfeeding |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to prednisolone or any componentSystemic fungal infectionAdministration of live or live-attenuated vaccines (due to immunosuppression)Ocular herpes simplex (due to risk of corneal perforation)
| Precautions | May cause immunosuppression and increased risk of infections., May cause adrenal suppression with prolonged use., May cause osteoporosis, cataracts, and glaucoma., May cause gastrointestinal perforation in patients with certain GI disorders., May cause growth suppression in children., May cause Cushing's syndrome with chronic use., May cause psychiatric disturbances., May mask signs of infection. |
| Food/Dietary | No significant food interactions reported. However, grapefruit may affect systemic absorption if high doses are used, though topical application minimizes systemic effects. Avoid alcohol as it may exacerbate gastric irritation if systemic absorption occurs. |
Loading safety data…
| Systemic corticosteroids are excreted in breast milk in low amounts. High-dose or long-term use may suppress infant adrenal function or growth. Predair Forte (prednisolone acetate) is considered compatible with breastfeeding if used short-term at moderate doses; monitor infant for signs of adrenal suppression (e.g., lethargy, poor feeding). |
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | Prednisolone acetate (PREDAIR FORTE) crosses the placenta. First trimester: increased risk of orofacial clefts (odds ratio ~3.4). Second/third trimester: associated with fetal adrenal suppression, low birth weight, and preterm delivery. Chronic use may cause intrauterine growth restriction. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose (steroid-induced hyperglycemia), and signs of infection. Fetal monitoring: serial ultrasound for growth restriction (every 4–6 weeks) and assessment of amniotic fluid volume. Consider nonstress test or biophysical profile after 32 weeks. |
| Fertility Effects | No direct impairment of fertility documented. However, systemic corticosteroids may disrupt menstrual cycles (anovulation) due to alteration of gonadotropin release; effects are reversible upon dose reduction/discontinuation. |
| Clinical Pearls | Predair Forte (prednisolone acetate 1%) is a potent ophthalmic corticosteroid. Taper dose gradually to avoid rebound inflammation. Monitor intraocular pressure (IOP) in patients with glaucoma or prolonged use. Contraindicated in epithelial herpes simplex keratitis and fungal infections. Use with caution in children due to risk of adrenal suppression. |
| Patient Advice | Shake the bottle well before each use. · Wash hands before instilling drops. · Do not touch the dropper tip to any surface to avoid contamination. · Remove contact lenses before use and wait at least 15 minutes before reinserting. · Do not use this medication for longer than prescribed. |